This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05386550
Recruitment Status : Recruiting
First Posted : May 23, 2022
Last Update Posted : March 6, 2024
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
EMD Serono ( EMD Serono Research & Development Institute, Inc. )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 5, 2027
Estimated Study Completion Date : December 16, 2030